Aspargo Labs Appoints Sam Backenroth as Chief Financial OfficerAdds experienced public-company finance executive to advance Aspargo’s corporate, commercial, and capital markets strategies
Aspargo Labs CEO to Participate in Panel Discussion at the American Urological Association Innovation Nexus ConferenceNEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a Pharmaceutical and MedTech company focused on converting the world's most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices, announced that Michael Demurjian, CEO & Chairman, will participate in a panel discussion at the American Urological Association (AUA) Innovation Nexus Conference in Las Vegas, Nevada, taking place on April 25, 2025.
Aspargo Labs Expands Global Leadership TeamNEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a specialty pharmaceutical and MedTech company focused on converting the world's most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices, announced the appointments of Jamel Benkreira as General Manager, United Kingdom & Ireland; and Dr. Pallav S. Shah as Director of Regulatory Affairs, Europe. These strategic appointments strengthen the Company's international leadership team as the Company continues to expand its liquid oral suspension portfolio and global market presence.
Aspargo Labs Appoints Mario Guralnik as Chief Regulatory OfficerAccomplished regulatory affairs veteran to lead company’s global regulatory strategy and drug product development
Aspargo Labs Appoints Harold D. Tamayo as Chief Financial OfficerExperienced financial leader joins as the company prepares for its public market entry
Aspargo Labs Appoints General Managers in Spain and Germany to Drive International ExpansionNEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmacy and MedTech company focused on reformulating the world’s most meaningful Rx and OTC medications into its novel oral suspension technology, announced the recent appointment of two highly experienced General Managers to accelerate Aspargo Labs’ global expansion: Álvaro Fernández in Spain and Dr. Marc van Unen in Germany.
Aspargo Labs Appoints Chief Marketing OfficerLife sciences marketing executive Andrew Chamlin will drive Aspargo Lab’s global growth in revolutionizing the way medications are delivered
